Franziska Michor, PhD

Franziska Michor, PhD


Contact Information

Office Phone Number





Franziska Michor, PhD

Dr. Michor is a Professor of Computational Biology in the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute, in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, and in the Department of Stem Cells and Regenerative Biology at Harvard University. Dr. Michor obtained her undergraduate training in mathematics and molecular biology from the University of Vienna, Austria, and her PhD from the Department of Organismic and Evolutionary Biology at Harvard University. Afterwards, she was awarded a fellowship from the Harvard Society of Fellows. From 2007 until 2010, she was an Assistant Professor in the Computational Biology Program at Memorial Sloan-Kettering Cancer Center. Dr. Michor is the director of the Dana-Farber Cancer Institute Physical Sciences-Oncology Center and the Center for Cancer Evolution. She has been the recipient of the Theodosius Dobzhansky Prize of the Society for the Study of Evolution, the Alice Hamilton Award , the Vilcek Prize for Creative Promise in Biomedical Science, the 36th Annual AACR Award for Outstanding Achievement in Cancer Research, and others. Dr. Michor's laboratory investigates the evolutionary dynamics of cancer initiation, progression, response to therapy, and emergence of resistance.



Professor of Computational Biology, Harvard T.H. Chan School of Public Health
Professor in the Department of Stem Cells and Regenerative Biology, Harvard University

Recent Awards

  • The 36th Annual AACR Award for Outstanding Achievement in Cancer Research 2016
  • NYSCF - Robertson Stem Cell Prize 2015
  • Vilcek Prize for Creative Promise in Biomedical Science 2015
  • Alice Hamilton Award 2012
  • Gerstner Young Investigator Award 2010
  • Leon Levy Young Investigator Award 2009
  • Austrian Scientists and Scholars in North America (ASCINA) Award 2008
  • Theodosius Dobzhansky Prize, Society for the Study of Evolution 2007
  • Junior Fellowship, Harvard Society of Fellows, Harvard University 2005-2008
  • Harold M. Wintraub Graduate Student Award, Fred Hutchinson Cancer Research Center, Seattle, Washington 2004
  • Austrian Mathematical Society Prize for paper titled, The Mathematics of Planetary Movement 2000


    Cancer evolution, mathematical modeling, cancer genomics, treatment response, cancer stem cells

    The research of our lab focuses on the evolutionary dynamics of cancer. Cancer emerges due to an evolutionary process in somatic tissue. The fundamental laws of evolution can best be formulated as exact mathematical equations. Therefore, the process of cancer initiation and progression is amenable to mathematical investigation. Current areas of research include cancer stem cells, evolution of drug resistance, and the dynamics of metastasis formation.

    Research Departments


      • A paracrine circuit of IL-1ß/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression. J Clin Invest. 2023 Sep 21. View in: Pubmed

      • H3K36 methylation maintains cell identity by regulating opposing lineage programmes. Nat Cell Biol. 2023 Aug; 25(8):1121-1134. View in: Pubmed

      • Tutorial: integrative computational analysis of bulk RNA-sequencing data to characterize tumor immunity using RIMA. Nat Protoc. 2023 08; 18(8):2404-2414. View in: Pubmed

      • Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity. Neuro Oncol. 2023 06 02; 25(6):1100-1112. View in: Pubmed

      • Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas. Clin Cancer Res. 2023 04 14; 29(8):1423-1428. View in: Pubmed

      • Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023 04 13; 141(15):1817-1830. View in: Pubmed

      • Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma. Cell Rep. 2023 03 28; 42(3):112235. View in: Pubmed

      • T-REX17 is a transiently expressed non-coding RNA essential for human endoderm formation. Elife. 2023 01 31; 12. View in: Pubmed

      • JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States. Cancer Res. 2023 01 18; 83(2):264-284. View in: Pubmed

      • Breast cancer prevention by short-term inhibition of TGFß signaling. Nat Commun. 2022 12 07; 13(1):7558. View in: Pubmed

      • Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. Sci Rep. 2022 Nov 09; 12(1):19055. View in: Pubmed

      • Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. Nat Commun. 2022 Sep 23; 13(1):5579. View in: Pubmed

      • In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies. Blood Adv. 2022 09 13; 6(17):5072-5084. View in: Pubmed

      • Spatial intra-tumor heterogeneity is associated with survival of lung adenocarcinoma patients. Cell Genom. 2022 Aug 10; 2(8). View in: Pubmed

      • Designing optimal allocations for cancer screening using queuing network models. PLoS Comput Biol. 2022 05; 18(5):e1010179. View in: Pubmed

      • Barcoded bulk QTL mapping reveals highly polygenic and epistatic architecture of complex traits in yeast. Elife. 2022 02 11; 11. View in: Pubmed

      • Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Exp Hematol. 2022 03; 107:14-19. View in: Pubmed

      • Response to comment on "Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2". Sci Transl Med. 2021 Oct 27; 13(617):eabj3222. View in: Pubmed

      • Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. NPJ Precis Oncol. 2021 Sep 21; 5(1):85. View in: Pubmed

      • Dissecting dual roles of MyoD during lineage conversion to mature myocytes and myogenic stem cells. Genes Dev. 2021 09 01; 35(17-18):1209-1228. View in: Pubmed

      • Topological isolation of developmental regulators in mammalian genomes. Nat Commun. 2021 08 12; 12(1):4897. View in: Pubmed

      • Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. Nat Commun. 2021 06 17; 12(1):3697. View in: Pubmed

      • The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer. JCI Insight. 2021 06 08; 6(11). View in: Pubmed

      • Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. iScience. 2021 Jun 25; 24(6):102651. View in: Pubmed

      • Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021 10; 11(10):2474-2487. View in: Pubmed

      • Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 2021 04 29; 137(17):2360-2372. View in: Pubmed

      • Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma. Nat Biomed Eng. 2021 04; 5(4):346-359. View in: Pubmed

      • Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature. 2021 04; 592(7853):302-308. View in: Pubmed

      • A Quantitative Paradigm for Decision-Making in Precision Oncology. Trends Cancer. 2021 04; 7(4):293-300. View in: Pubmed

      • Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell. 2021 03 04; 28(3):514-523.e9. View in: Pubmed

      • How Does Large-Scale Genomic Analysis Shape Our Understanding of COVID Variants in Real Time? Cell Syst. 2021 02 17; 12(2):109-111. View in: Pubmed

      • Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML. Nat Commun. 2021 01 11; 12(1):245. View in: Pubmed

      • Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. Sci Transl Med. 2020 12 09; 12(573). View in: Pubmed

      • Circadian clock effects on cellular proliferation: Insights from theory and experiments. Curr Opin Cell Biol. 2020 12; 67:17-26. View in: Pubmed

      • ESTIpop: a computational tool to simulate and estimate parameters for continuous-time Markov branching processes. Bioinformatics. 2020 08 01; 36(15):4372-4373. View in: Pubmed

      • Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance. Cancer Res. 2020 08 15; 80(16):3372-3382. View in: Pubmed

      • Accelerating massively parallel hemodynamic models of coarctation of the aorta using neural networks. Sci Rep. 2020 06 11; 10(1):9508. View in: Pubmed

      • Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell. 2020 06 18; 78(6):1096-1113.e8. View in: Pubmed

      • Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020 05 11; 11(1):2350. View in: Pubmed

      • Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations. Cancer Res. 2020 05 15; 80(10):2017-2030. View in: Pubmed

      • Ascl2-Dependent Cell Dedifferentiation Drives Regeneration of Ablated Intestinal Stem Cells. Cell Stem Cell. 2020 03 05; 26(3):377-390.e6. View in: Pubmed

      • DIFFpop: a stochastic computational approach to simulate differentiation hierarchies with single cell barcoding. Bioinformatics. 2019 10 01; 35(19):3849-3851. View in: Pubmed

      • Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms. Haematologica. 2020 03; 105(3):e91-e94. View in: Pubmed

      • Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2019 07; 21(7):879-888. View in: Pubmed

      • Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS One. 2019; 14(4):e0215409. View in: Pubmed

      • Stochastic Evolution of Pancreatic Cancer Metastases During Logistic Clonal Expansion. JCO Clin Cancer Inform. 2019 03; 3:1-11. View in: Pubmed

      • KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. 2019 Feb 11; 35(2):330-332. View in: Pubmed

      • Hidden heterogeneity and circadian-controlled cell fate inferred from single cell lineages. Nat Commun. 2018 12 18; 9(1):5372. View in: Pubmed

      • Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies. JCO Clin Cancer Inform. 2018 12; 2:1-12. View in: Pubmed

      • Currently available bulk sequencing data do not necessarily support a model of neutral tumor evolution. Nat Genet. 2018 12; 50(12):1620-1623. View in: Pubmed

      • KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. 2018 12 10; 34(6):939-953.e9. View in: Pubmed

      • Fitness variation in isogenic populations leads to a novel evolutionary mechanism for crossing fitness valleys. Commun Biol. 2018; 1:151. View in: Pubmed

      • Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun. 2018 09 04; 9(1):3588. View in: Pubmed

      • A PDGFRa-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nat Commun. 2018 08 06; 9(1):3116. View in: Pubmed

      • Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018; 4:10. View in: Pubmed

      • Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes Dev. 2018 04 01; 32(7-8):512-523. View in: Pubmed

      • Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS Comput Biol. 2018 01; 14(1):e1005924. View in: Pubmed

      • The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation. Ann Oncol. 2018 01 01; 29(1):264-270. View in: Pubmed

      • Nuclear topology modulates the mutational landscapes of cancer genomes. Nat Struct Mol Biol. 2017 Nov; 24(11):1000-1006. View in: Pubmed

      • mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors. Cancer Discov. 2017 12; 7(12):1450-1463. View in: Pubmed

      • Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer. Nature. 2017 09 28; 549(7673):543-547. View in: Pubmed

      • Analysis of somatic microsatellite indels identifies driver events in human tumors. Nat Biotechnol. 2017 Oct; 35(10):951-959. View in: Pubmed

      • Estimating mono- and bi-phasic regression parameters using a mixture piecewise linear Bayesian hierarchical model. PLoS One. 2017; 12(7):e0180756. View in: Pubmed

      • SIApopr: a computational method to simulate evolutionary branching trees for analysis of tumor clonal evolution. Bioinformatics. 2017 Jul 15; 33(14):2221-2223. View in: Pubmed

      • Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov. 2017 10; 7(10):1098-1115. View in: Pubmed

      • Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells. Nucleic Acids Res. 2017 Jun 02; 45(10):e77. View in: Pubmed

      • Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. Cancer Res. 2017 07 15; 77(14):3908-3921. View in: Pubmed

      • The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 04 04; 19(1):218-224. View in: Pubmed

      • Mathematical Modeling Links Pregnancy-Associated Changes and Breast Cancer Risk. Cancer Res. 2017 06 01; 77(11):2800-2809. View in: Pubmed

      • Distance in cancer gene expression from stem cells predicts patient survival. PLoS One. 2017; 12(3):e0173589. View in: Pubmed

      • Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol. 2017 02 01; 28(2):278-284. View in: Pubmed

      • Proceedings of the third international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2017 02; 28(2):167-176. View in: Pubmed

      • Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605. View in: Pubmed

      • Probabilistic Modeling of Reprogramming to Induced Pluripotent Stem Cells. Cell Rep. 2016 12 20; 17(12):3395-3406. View in: Pubmed

      • A computational strategy to adjust for copy number in tumor Hi-C data. Bioinformatics. 2016 12 15; 32(24):3695-3701. View in: Pubmed

      • Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet. 2016 10; 48(10):1119-30. View in: Pubmed

      • ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells. Sci Rep. 2016 07 26; 6:25956. View in: Pubmed

      • Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease. Am J Hematol. 2016 09; 91(9):931-7. View in: Pubmed

      • Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214. View in: Pubmed

      • The mathematics of cancer: integrating quantitative models. Nat Rev Cancer. 2015 Dec; 15(12):730-45. View in: Pubmed

      • Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. Cell. 2015 Nov 19; 163(5):1059-1063. View in: Pubmed

      • Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients. PLoS One. 2015; 10(11):e0141665. View in: Pubmed

      • An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer. PLoS Comput Biol. 2015 Sep; 11(9):e1004350. View in: Pubmed

      • In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet. 2015 Oct; 47(10):1212-9. View in: Pubmed

      • CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Rep. 2015 Jul 28; 12(4):622-35. View in: Pubmed

      • The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. View in: Pubmed

      • Optimization of radiation dosing schedules for proneural glioblastoma. J Math Biol. 2016 Apr; 72(5):1301-36. View in: Pubmed

      • Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med. 2015 May; 21(5):440-8. View in: Pubmed

      • DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer. 2015 Apr 09; 15:242. View in: Pubmed

      • Polyploidy can drive rapid adaptation in yeast. Nature. 2015 Mar 19; 519(7543):349-52. View in: Pubmed

      • Stochastic tunneling and metastable states during the somatic evolution of cancer. Genetics. 2015 Apr; 199(4):1213-28. View in: Pubmed

      • JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015 Mar; 5(3):316-31. View in: Pubmed

      • Epigenetic diversity in hematopoietic neoplasms. Biochim Biophys Acta. 2014 Dec; 1846(2):477-84. View in: Pubmed

      • Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica. 2014 Nov; 99(11):1701-9. View in: Pubmed

      • Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell. 2014 Aug 11; 26(2):288-300. View in: Pubmed

      • Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature. 2014 Oct 02; 514(7520):54-8. View in: Pubmed

      • Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014 Aug 14; 512(7513):155-60. View in: Pubmed

      • On the validity of using increases in 5-year survival rates to measure success in the fight against cancer. PLoS One. 2014; 9(7):e83100. View in: Pubmed

      • Histone modifications are associated with transcript isoform diversity in normal and cancer cells. PLoS Comput Biol. 2014 Jun; 10(6):e1003611. View in: Pubmed

      • FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014 Aug; 3(4):835-44. View in: Pubmed

      • Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014 Apr 03; 106(5). View in: Pubmed

      • Understanding tissue context influences on intratumour heterogeneity. Nat Cell Biol. 2014 Apr; 16(4):301-2. View in: Pubmed

      • Evolution of acquired resistance to anti-cancer therapy. J Theor Biol. 2014 Aug 21; 355:10-20. View in: Pubmed

      • Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1873-83. View in: Pubmed

      • Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell. 2014 Jan 30; 156(3):603-616. View in: Pubmed

      • Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014 Feb 13; 6(3):514-27. View in: Pubmed

      • Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 2014 Mar 01; 74(5):1338-48. View in: Pubmed

      • Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 2014 Mar 13; 123(11):1699-708. View in: Pubmed

      • Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. Br J Haematol. 2013 Dec; 163(5):674-6. View in: Pubmed

      • Stochastic Tunneling of Two Mutations in a Population of Cancer Cells. PLoS One. 2013; 8(6):e65724. View in: Pubmed

      • Patterns of proliferative activity in the colonic crypt determine crypt stability and rates of somatic evolution. PLoS Comput Biol. 2013; 9(6):e1003082. View in: Pubmed

      • Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell. 2013 Jul 03; 13(1):117-30. View in: Pubmed

      • Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res. 2013 Sep; 23(9):1434-45. View in: Pubmed

      • Genomic characterization of metastatic urothelial carcinoma. J Clin Oncol. 2013 Feb 20; 31(6_suppl):247. View in: Pubmed

      • Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):279. View in: Pubmed

      • Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013 Mar 10; 31(8):1070-80. View in: Pubmed

      • Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet. 2013; 9(1):e1003137. View in: Pubmed

      • DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes. Nat Commun. 2013; 4:1502. View in: Pubmed

      • A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013; 3:1449. View in: Pubmed

      • Analyzing the association of SCNA boundaries with replication timing. Nat Biotechnol. 2012 Nov; 30(11):1045-6. View in: Pubmed

      • Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J Thorac Oncol. 2012 Oct; 7(10):1583-93. View in: Pubmed

      • Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2012 Jun; 2(6):503-11. View in: Pubmed

      • Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. Haematologica. 2012 Oct; 97(10):1553-61. View in: Pubmed

      • Evolution of the cancer genome. Trends Genet. 2012 Apr; 28(4):155-63. View in: Pubmed

      • A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability. PLoS Comput Biol. 2012; 8(2):e1002370. View in: Pubmed

      • Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012 Jan 20; 148(1-2):362-75. View in: Pubmed

      • Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012 Mar 01; 18(5):1323-33. View in: Pubmed

      • A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol. 2012 Jan; 8(1):e1002337. View in: Pubmed

      • Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One. 2011; 6(11):e27682. View in: Pubmed

      • DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nat Biotechnol. 2011 Nov 20; 29(12):1103-8. View in: Pubmed

      • Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 05; 8(6):2069-79. View in: Pubmed

      • The probable cell of origin of NF1- and PDGF-driven glioblastomas. PLoS One. 2011; 6(9):e24454. View in: Pubmed

      • What does physics have to do with cancer? Nat Rev Cancer. 2011 Aug 18; 11(9):657-70. View in: Pubmed

      • DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood. 2011 Sep 29; 118(13):3559-69. View in: Pubmed

      • Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011 Jul 06; 3(90):90ra59. View in: Pubmed

      • DNA secondary structures and epigenetic determinants of cancer genome evolution. Nat Struct Mol Biol. 2011 Jul 03; 18(8):950-5. View in: Pubmed

      • Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011 Aug 11; 118(6):1622-31. View in: Pubmed

      • A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011 May 12; 473(7346):230-3. View in: Pubmed

      • Evolutionary dynamics of intratumor heterogeneity. PLoS One. 2011 Mar 30; 6(3):e17866. View in: Pubmed

      • Intratumor heterogeneity in evolutionary models of tumor progression. Genetics. 2011 Jun; 188(2):461-77. View in: Pubmed

      • Stochastic dynamics of cancer initiation. Phys Biol. 2011 Feb; 8(1):015002. View in: Pubmed

      • Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis. J Theor Biol. 2011 Mar 21; 273(1):207-15. View in: Pubmed

      • The therapeutic implications of plasticity of the cancer stem cell phenotype. PLoS One. 2010 Dec 17; 5(12):e14366. View in: Pubmed

      • The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila). 2010 Nov; 3(11):1361-4. View in: Pubmed

      • A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A. 2010 Oct 12; 107(41):17604-9. View in: Pubmed

      • A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. Am J Pathol. 2010 Aug; 177(2):908-17. View in: Pubmed

      • Evolutionary dynamics of tumor progression with random fitness values. Theor Popul Biol. 2010 Aug; 78(1):54-66. View in: Pubmed

      • A differentiation-based phylogeny of cancer subtypes. PLoS Comput Biol. 2010 May 06; 6(5):e1000777. View in: Pubmed

      • Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010 Feb; 120(2):636-44. View in: Pubmed

      • Evolution of resistance to anti-cancer therapy during general dosing schedules. J Theor Biol. 2010 Mar 21; 263(2):179-88. View in: Pubmed

      • The evolution of tumor metastases during clonal expansion. J Theor Biol. 2010 Mar 07; 263(1):30-44. View in: Pubmed

      • Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol. 2009 Nov; 5(11):e1000557. View in: Pubmed

      • A progenitor cell origin of myeloid malignancies. Proc Natl Acad Sci U S A. 2009 Sep 29; 106(39):16616-21. View in: Pubmed

      • Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol. 2009 Sep; 5(9):e1000503. View in: Pubmed

      • Evolutionary theory of cancer. Ann N Y Acad Sci. 2009 Jun; 1168:23-51. View in: Pubmed

      • A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica. 2008 Aug; 93(8):1219-26. View in: Pubmed

      • Mathematical models of cancer stem cells. J Clin Oncol. 2008 Jun 10; 26(17):2854-61. View in: Pubmed

      • The evolution of two mutations during clonal expansion. Genetics. 2007 Dec; 177(4):2209-21. View in: Pubmed

      • Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia. Trends Pharmacol Sci. 2007 May; 28(5):197-9. View in: Pubmed

      • The emergence of tumor metastases. Cancer Biol Ther. 2007 Mar; 6(3):383-90. View in: Pubmed

      • (A)symmetric stem cell replication and cancer. PLoS Comput Biol. 2007 Mar 16; 3(3):e53. View in: Pubmed

      • Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells. 2007 May; 25(5):1114-8. View in: Pubmed

      • Mathematical models of targeted cancer therapy. Br J Cancer. 2006 Nov 06; 95(9):1136-41. View in: Pubmed

      • The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proc Natl Acad Sci U S A. 2006 Oct 03; 103(40):14931-4. View in: Pubmed

      • Successful therapy must eradicate cancer stem cells. Stem Cells. 2006 Dec; 24(12):2603-10. View in: Pubmed

      • Evolution of resistance during clonal expansion. Genetics. 2006 Apr; 172(4):2557-66. View in: Pubmed

      • Dynamics of metastasis suppressor gene inactivation. J Theor Biol. 2006 Aug 07; 241(3):676-89. View in: Pubmed

      • Genetic instability and clonal expansion. J Theor Biol. 2006 Jul 07; 241(1):26-32. View in: Pubmed

      • Genetic instability and the quasispecies model. J Theor Biol. 2006 Jul 21; 241(2):216-22. View in: Pubmed

      • Evolution of resistance to cancer therapy. Curr Pharm Des. 2006; 12(3):261-71. View in: Pubmed

      • Stochastic dynamics of metastasis formation. J Theor Biol. 2006 Jun 21; 240(4):521-30. View in: Pubmed

      • Dynamics of colorectal cancer. Semin Cancer Biol. 2005 Dec; 15(6):484-93. View in: Pubmed

      • Synergy and discounting of cooperation in social dilemmas. J Theor Biol. 2006 Mar 21; 239(2):195-202. View in: Pubmed

      • Dynamics of chronic myeloid leukaemia. Nature. 2005 Jun 30; 435(7046):1267-70. View in: Pubmed

      • Chromosomal instability and human cancer. Philos Trans R Soc Lond B Biol Sci. 2005 Mar 29; 360(1455):631-5. View in: Pubmed

      • Can chromosomal instability initiate tumorigenesis? Semin Cancer Biol. 2005 Feb; 15(1):43-9. View in: Pubmed

      • Virus evolution within patients increases pathogenicity. J Theor Biol. 2005 Jan 07; 232(1):17-26. View in: Pubmed

      • Population genetics of tumor suppressor genes. J Theor Biol. 2005 Mar 07; 233(1):15-23. View in: Pubmed

      • Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med. 2004 Nov 15; 200(10):1243-56. View in: Pubmed

      • Some basic properties of immune selection. J Theor Biol. 2004 Jul 21; 229(2):179-88. View in: Pubmed

      • Evolutionary dynamics of tumor suppressor gene inactivation. Proc Natl Acad Sci U S A. 2004 Jul 20; 101(29):10635-8. View in: Pubmed

      • Linear model of colon cancer initiation. Cell Cycle. 2004 Mar; 3(3):358-62. View in: Pubmed

      • Dynamics of cancer progression. Nat Rev Cancer. 2004 Mar; 4(3):197-205. View in: Pubmed

      • Stochastic tunnels in evolutionary dynamics. Genetics. 2004 Mar; 166(3):1571-9. View in: Pubmed

      • Evolutionary dynamics of invasion and escape. J Theor Biol. 2004 Jan 21; 226(2):205-14. View in: Pubmed

      • Evolutionary dynamics of escape from biomedical intervention. Proc Biol Sci. 2003 Dec 22; 270(1533):2573-8. View in: Pubmed

      • Somatic selection for and against cancer. J Theor Biol. 2003 Dec 07; 225(3):377-82. View in: Pubmed

      • The linear process of somatic evolution. Proc Natl Acad Sci U S A. 2003 Dec 09; 100(25):14966-9. View in: Pubmed

      • Stochastic elimination of cancer cells. Proc Biol Sci. 2003 Oct 07; 270(1528):2017-24. View in: Pubmed

      • Local regulation of homeostasis favors chromosomal instability. Curr Biol. 2003 Apr 01; 13(7):581-4. View in: Pubmed

      • Evolution: the good, the bad and the lonely. Nature. 2002 Oct 17; 419(6908):677, 679. View in: Pubmed


      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Center for Life Sciences CLS 11029 Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Center for Life Sciences CLS 11029 Boston, MA 02215
      Get Direction
      42.3374, -71.1082